 BOTHELL, Wash., March 02, 2021 GLOBE NEWSWIRE -- Cocrystal Pharma, Inc. Nasdaq: COCP, Cocrystal or the Company, a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. 